In particular, the increase in cell types such as CD8+_T_cells and enhanced type_II_IFN_response, inflammation-promoting effects, and other processes all indicated improved immunity, thus confirming that the cancer was in late stages with a worse patient prognosis. This evidence concerns the gene CD8A and cancer.